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Abstract
THE EFFECT OF 48 HR GLUCOSE ADMINISTRATION
ON THE HEPATIC P-450 SYSTEM

by
John N. Buchholz

The administration of glucose for 48 hrs to mice
resulted in a shift of the dose response curve of pentobarbital, an indication that glucose administration
significantly sensitized the animals to the effects of the
drug.

Glucose administration produced a reduction in the

catalytic activity of hepatic microsomal P-450 as measured
by the in vitro conversion of p-Nitroanisole to pNitrophenol.
The administration of glucose to rats for 48 hrs
resulted in prolonged anesthesia after the administration of
pentobarbital.

The spectral binding of hexobarbital and

methadone to hepatic microsomal P-450 was f otind to be
significantly reduced following glucose administration.

The

changes in spectral binding were observed in the absence of
any significant change in the microsomal P-450 content.

The

changes in the spectral binding of hexobarbital and methadone to P-450 in glucose treated animals might suggest that
glucose administration is causing a qualitative or conformational change in hepatic microsomal P-450 enzymes.

Glucose

administration resulted in an increase in the cytosolic
protein content which may possibly indicate that glucose is
inducing enzymes responsible for its metabolism and/or the
synthesis of lipids from glucose.
Glucose treatment produced a decrease in hepatic glycogen content and an increase in total microsomal lipid, phospholipid, and fatty acid content.

Specific fatty acid and

phospholipid contents were also measured following glucose
administration.

The results showed that there was an

increase in microsomal palmitic, palmitoleic, stearic and
oleic acids as well as the phospholipids phosphatidylcholine
and phosphatidylethanolamine.

Changes in lipid content and

specific fatty acid content have been shown to be associated
with changes in microsomal P-450 activity and the binding of
various substrates to P-450.

The data reported in these

studies suggest that glucose administration was associated
with quantitative alterations in specific microsomal lipid
content and that the lipid changes could have influenced the
activity of microsomal P-450 and the binding of drug substrates to P-450.
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Chapter 1
INTRODUCTION
The endoplasmic reticulum of the eukaryotic cell
fulfills a number of vital roles in the regulation of
carbohydrate and lipid metabolism and in the biosynthesis of
biochemical entities such as cholesterol and steroids.

The

finding that this subfraction of the cell is also involved
in the metabolism and hence detoxification of xenobiotics
has made the endoplasmic reticulum a major focus in the
pharmacological subspecialty known as drug metabolism.

The

bulk of drug metabolism appears to be carried out by enzymes
located in the endoplasmic reticulum of hepatic cells (1).
The hepatic endoplasmic reticulum is an intracellular
membrane which can be subdivided into two distinct subfractions known as the rough endoplasmic reticulum (RER) and
smooth endoplasmic reticulum (SER).

The RER contains

ribonucleoprotein particles known as ribosomes which are
involved in the synthesis of proteins secreted from the cell
and of proteins destined for incorporation into the endoplasmic reticulum and other subcellular membranes.

The SER

although not capable of synthesizing proteins, is involved
in numerous aspects of lipid metabolism and monooxygenations
of steroids and xenobiotics.
Both the SER and RER contain the monooxygenase system
which is made up of cytochrome P-450, NADPH-cytochrome P-450
reductase (a FAD- and FMN-containing flavoprotein) and
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phosphatidylcholine as well as other phospholipids and
neutral lipids.

The lipid components are necessary for

optimal monooxygenase activity (1).
The cytochrome P-450 system prevents the progressive
accumulation of lipophilic xenobiotics.

Thus detoxification

appears to be one function of the P-450 system which is
essential to the survival of humans and other animals alike
( 1) •

There are a great multiplicity of substrates which
undergo hydroxylations involving cytochrome P-450.

This

observation has raised doubts concerning the homogeneity of
P-450.

The theory of heterogeneous P-450's has been able to

account for the fact that a single substrate such as testosterone can undergo several hydroxylations at different carbon atoms.

Furthermore, the rates of each hydroxylation can

be altered following pretreatment with different inducing
agents.

The existence of multiple forms of P-450 has been

established on the basis of spectrophotometric, electrophoretic and immunological methods (2).

These multiple

forms of P-450 have different substrate selectivities with
varying degrees of overlap, are genetically determined and
they appear to be individually substrate-inducible.

Induc-

tion of rat liver microsomal P-450 with phenobarbital and 3methylchloanthrene appears to produce two spectrally different enzymes, having absorption maxima at 450 and 448 nm
respectively (3).

Later studies of this phenomenon have
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shown that a total of seven cytochromes appear to be induced
by the two inducing agents (4).

The heterogeneity of the

monooxygenase system has the virtue of great versatility
with respect to its ability to meet the challenge of
detoxifying many different chemicals utilized in medicine
and industry today.
Phospholipids and Fatty Acids
in the Microsomal System and
Their Relationship to P-450.
cytochrome P-450 is an integral protein embedded in the
membrane matrix of the·endoplasmic reticulum.

Consequently,

the properties of these protein components and the rates of
specific reactions they catalyze will likely be influenced
by the nature of the lipid components of the membrane, in
particular phospholipids.

The :membrane matrix provides a

hydrophobic environment for P-450 enzymes, which mostly
utilize lipophilic substrates.

Thus the membrane consti-

tutes a reservoir for the substrates of P-450 and the
membrane composition may possibly influence the type of
substrate-P-450 interactions that occur (1).
The phospholipid composition of the hepatic endoplasmic
reticulum membrane is 55% phosphatidylcholine (PC), 20-25%
phosphatidylethanolamine (PE), 8-10% phosphatidylserine
(PS), 5-10% phosphatidylinositol (PI), and 4-7% sphingomyelin (SM), reveals that the membrane is negatively charged
at neutral pH.

The. ratio of PC to PE is very constant (2 .,.5)

which suggests that the proper ratio of PC to PE may be very
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important in the normal functioning of membrane bound P-450
(5,6).

Analysis of the fatty acid composition of the rat

hepatic endoplasmic reticulum showed that the predominant
fatty acids (approx. 90%) esterified to the number 1 position of phosphatidylcholine and phosphatidylethanolamine are
palmitic (C16:0) and oleic acid (C18:0).

At the number 2

position of phosphatidylcholine and ethanolamine the
predominant fatty acids (greater than 90%) are arachidonic
(C20:4) and trilinolein (C18:2).

The fluidity of the micro-

somal membrane appears to be determined by the fatty acid
constituents on the phospholipids and can be altered with
changes in dietary composition of lipids and fatty acids
(6,7).

Changes in fatty acid composition of the microsomal

membrane which apparently produce alterations in membrane
fluidity (6), also results in changes in the catalytic
activity of microsomal P-450 (7).

For example the feeding

of 3%-10% corn oil diets to rats results in a decrease in
the duration of hexobarbital induced anesthesia with an
associated increase in the hepatic microsomal P-450 mediated
metabolism of hexobarbital and ethylmorphine (7).
Isolation and reconstitution represents the classical
biochemical approach to the study of multi-enzyme systems.
In early studies the P-450 system was initially resolved
into 3 components, P-450, NADPH cytochrome P-450 reductase
and a heat stable factor (8).

The latter component was

eventually identified as a lipid, specifically PC (9).
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Different types of phospholipids have been investigated for
stimulatory properties of the P-450 system (9).

It appeared

that dilauryl phosphatidylcholine was the most efficient
lipid in stimulating the activity of the P-450 system in
reconstitution experiments (10).
The components of the microsomal P-450 system are
integrated into the hydrophobic interior of the membrane and
are in intimate contact with the fatty acyl chains of the
phospholipids.

It remains reasonable to expect that there

is a pronounced interdependency between the function of P450 and the structure of the phospholipid and the physical
state of the lipid in the microsomal membrane.

Extraction

of the hepatic microsomes with organic solvents will remove
all neutral lipids and 80% of the phospholipid from the
membrane, and results in a nearly complete inactivation of
P-450 dependent hydroxylase activity (11).

The activity of

the monooxygenase system was found to be restored by the
addition of PC to the lipid free preparations (12).

These

studies seem to suggest that phospholipid has a role in
determining the activity of the P-450 monooxygenase system
and that added lipid could renature P-450, partially
denatured by organic solvent extraction.
The importance of membrane phospholipid for substrate
binding and catalysis was recognized over a decade ago.
Treatment of microsomes with phospholipase A resulted in a
conversion of P-450 to P-420 (13).

Phospholipase C
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treatment of solublized microsomes will also result in a
conversion of P-450 to P-420 which reduces the binding of
various substrates to P-450 and decreases the rate of drug
metabolism (14,15).

Isooctane extraction of liver

microsomes, which removes PC and PE will significantly
reduce the binding of drug substrates to P-450 and
consequently their metabolism (16).

There seems to be no

simple explanation for the phenomena described above.
However one possible explanation is that the lipid
components of the membrane maintain the appropriate
conformational states of P-450 which are necessary for their
catalytic activity (16).

The results do emphasize the

interdependency between phospholipids and the ability of
P-450 to bind and oxidize substrates.
The P-450 enzymes exhibit a characteristic spin state
alteration when substrates bind to the enzymes.

Cytochrome

P-450 can be either in a low spin state or a high spin
state.

A transition from a low to high spin state and vice

versa results in conformational changes in the P-450.

The

high spin transition (type 1) is characterized by an absorption maximum at 380-385 nm and a minimum at 415-420 nm.

Low

spin transition (type 2) is characterized by an absorption
minimum at 380-385 nm and a maximum at 415-420 nm
(17,18,19).

The binding of cholesterol to specific P-450

(P-450cam) results in a change from the low spin state to a
high spin state and the high spin form of the P-450 has a

-

-

~----------------------------------
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higher affinity for cholesterol than the low spin form of
P-450.

Furthermore adrenodoxin (a synthetic steroid) acti-

vates the binding of cholesterol by enhancing the proportion
of P-450 in the high spin state {20).

It appears that some

ligands such as cholesterol bind preferably to the high spin
forlil of P-450 where as other ligands such as pregnenolone
bind preferably to the low spin form of P-450 (20).

From

these observations it appears that the relative affinity of
P-450 enzymes for similar substrates is dependent on the
unique conformation of these enzymes associated with their
spin states (21).

In the absence of exogenous substrates

there is an equilibrium between the high and low spin states
of microsomal P-450 (22).

Investigations considering what

components of the microsomal membrane are important in
maintaining spin state equilibria have revealed that phospholipids and fatty acid moieties on the phospholipids have
significant effects on the spin state equilibria of P-450
(23,24).
One of the major roles of the membrane matrix in the
P-450 mediated catalysis is to provide a hydrophobic environment suitable for the hydrophobic compounds which are
substrates forP-450.

A relatively low affinity of the sub-

strate for P--450 can be compensated for by the partitioning
of a substrate in the membrane, which concentrates hydrophobic substrates in the membrane interior (25).

More

recent data suggest that the substrate binding site for
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P-450 is in intimate contact with the membrane lipid phase
(26) and that the hydroxylation rate for a substrate such as
cholesterol is sensitive to the fatty acid composition of
the lipids (27).
The hepatic microsomal cytochrome P-450 system has been
found not only to be involved in the oxidation of xenobiotic
substances, but also oxidizes endogenous substrates such as
steroids (28) and fatty acids on phospholipids in the microsomal membrane (29).

More than a decade ago it was sug-

gested that.fatty acids and some drugs may be oxidized by a
common hepatic NADPH-dependent mixed function oxidase system
(30).

Fatty acids such as oleic acid and saturated straight

chain fatty acids also appear to be oxidized by the hepatic
microsomal P-450 (31).

The oxidation of fatty acids in

microsomal lipids such as arachidonic acid by hepatic P-450
appears to facilitate the conversion of arachidonic acid to
prostaglandins (32).

Fatty acid oxidation by P-450 has been

suggested as a mechanism which may facilitate lipid turnover
in the microsomal membrane and furthermore fatty acids such
as lauric acid seem to be pref erred substrates for hydroxylation as compared to the hydroxylation of drugs (33).
Microsomal enzymes are involved in the synthesis of PC,
PS, PE and the sphingolipids which suggests that the microsomal enzymes may play an important role in determining the
optimal lipid environment for the P-450 enzyme system (34).
From the preceding discussion it appears that the microsomal
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P-450 system which metabolizes endogenous and xenobiotic
substances is a membrane bound system, and that there are a
number of factors that can apparently affect the activity of
this system.
A major concern of contemporary medicine is the adverse
effects resulting from the clinical use of pharmacologic
agents.

The metabolic clearance of drugs regulates in part

the duration of action and adverse reactions involved in the
use of pharmacological agents.

Nutritional factors, includ-

ing proteins, carbohydrates, fats, vitamins and minerals
affect the efficiency of metabolic reactions and hence the
clearance of various drugs.

Since the majority of foreign

compounds are metabolized by hepatic membrane bound enzymes,
any factor that alters the binding of substrates to these
enzymes is likely to cause a change in the rate of metabolism and hence the activity of a drug {35,36).
There have been a number of factors that have been
shown to affect the duration of ·action of sedative hypnotics
such as barbiturates.

Starvation of an animal for a short

period of time results in increased barbiturate induced
anesthesia (37,39,40).

It was suggested that starvation may

cause a loss of hepatic microsomal protein which apparently
results in decreased metabolism of the barbiturates and
hence prolonged effect (39).

Rats that are fed a diet high

in carbohydrates exhibit a prolonged sleep time after the
administration of pentobarbital and barbital (41).
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Vitamin B deficient diets when fed to rats resulted in
longer sleep times after the administration of thiopental
and pentobarbital.

The deficiency of nicotinic acid

presumably leads to a nicotinamide adenine dinucleotide
phosphate (NADPH) depletion which is a necessary component
in the oxidation of these drugs and thus may be responsible
for the observed effect (42,43).
Rats that are given an intraperitoneal (i. p.)
injection of glucose or fructose over a 7 day period will
exhibit decreased hepatic P-450 content and ethylmorphine Ndemethylase activity (44).

These data suggest that glucose

or sucrose is altering the P-450 content of the hepatic cell
and thus its ability to metabolize drugs.

Mice that are

allowed to drink a 30% glucose solution for 48 hrs have been
studied in regards to barbiturate induced anesthesia, duration of opiate analgesia and the in vitro hepatic microsomal
metabolism of various barbiturates and opiate analgesics
(45,46,47).

Animals treated with glucose were found to

sleep significantly longer than controls when administered
various barbiturates and the analgesic effect of representative opiates was extended (45,46,47).

Furthermore the in

vitro hepatic microsomal metabolism of representative
opiates and barbiturates was found to be compromised in the
glucose treated animals.

Kinetic studies on the in vitro

metabolism of hexobarbital and methadone in glucose treated
mice showed significant changes in the kinetic parameters Km
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and Vmax (46,47).

The changes in the kinetic parameters

could not be related to quantitative changes in P-450
content since the P-450 content was not significantly
altered by 48 hr glucose treatment (46,47).
Other studies were designed to test the possibility
that a metabolite of glucose or glucose itself might act as
an inhibitor of P-450 activity (48).

In these studies the

cytosolic fraction from treated animals was reconstituted
with the microsomes from the control animals to see if the
in vitro metabolism of the substrate p-Nitroanisole (PNA) by
control microsomes could be inhibited by some component in
the cytosol from glucose treated animals.

The results

showed that following treatment with glucose the microsomes
from the glucose treated animals were significantly impaired
in their ability to·metabolize PNA as compared to control
microsomes.

The results also showed that adding cytosol

from treated animals to the microsomes from control animals
did not change the rate of metabolism of PNA by the control
microsomes.

From the data presented above it seems clear

that the metabolism of barbiturates and opiate analgesics is
reduced as a result of 48 hr glucose treatment.

Following

the decrease in the metabolism of these compounds, they
would then presumably accumulate in the blood which would
account for the increase in the duration of action after
glucose administration (48).
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There are fundamental questions that could be asked
concerning the glucose effect on the microsomal metabolism
of barbiturates and opiate analgesics.

The first question

is, does glucose or one of its metabolites affect the activity of the P-450 system indirectly by causing a quantitative change in the amount of P-450 in the microsomes?

The

second question is, can glucose be converted to other substances such as fatty acids and lipids which can then be
deposited into the microsomal membrane and produce. a change
in the activity of the microsomal P-450?

The studies com-

pleted here were designed first, to further clarify the in
vivo effects of glucose administration on pentobarbital
induced anesthesia by examining the dose response curve of
pentobarbital in mice; second, to examine the effect of
glucose treatment on the relative activity of hepatic microsomal P•450 in mice utilizing reconstitution studies with
microsomes and cytosolic components; third, to examine the
e-ffect of glucose administration on pentobarbital induced
anesthesia in the rat and the effect of glucose administration on the spectral binding of hexobarbital and methadone to rat hepatic microsomal P-450; fourth, to observe
possible changes in the content of hepatic cytosolic
protein, glycogen, total microsomal phospholipid, total
microsomal fatty acids, specific microsomal fatty acids and
phospholipids followinq glucose administration.

Chapter 2
METHODS
The Effect of.Glucose Administration
on.the.Dose Response Curve of
Pentobarbital in Mice and the
in Vitro Metabolism of
p~Nitroanisole by Mouse
Liver Fractions
Male swiss Webster mice (Simonsen Laboratories, Gilroy
Ca.) weighing 25-28 g were maintained for one week after
arrival and then randomized into control and glucose treated
groups for each experiment.

The control groups received

water and food (ad libitum) while the glucose treated groups
received a 30% glucose solution for 48 hrs and food (ad
libitum).

At 48 hrs the animals were injected i.p. with

pentobarbital at dose levels of 35, 40, 45, 50, and 55
mg/kg.

Induction of sleep was determined by the loss of the

righting reflex.

Dose response data was analyzed by the

previously published method of Litchfield and Wilcoxin (38).
Mice from the control and glucose treated groups were
randomly selected, sacrificed by cervical dislocation and
the livers removed.

The 9000 xg and microsomal liver frac-

tions were prepared as described by Dixon et al. (40).
demethylation of p-Nitroanisole was assayed by the previously published method of Kato and Gillette (49).
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The

14
The Effect of 48 hr Glucose
Administration on Pentobarbital
Sleep Time in Rats
Male rats (Simonsen Laboratories, Gilroy Ca.) weighing
200-225 g were randomized into control and glucose treated
groups.

Both groups were treated in the same manner as the

mice mentioned above.

At 48 hrs the animals were injected

i.p. with a dose of pentobarbital (70 mg/kg).

Sleep time

was determined as the time elapsed between the loss and reacquisition of the righting reflex.
Assay.of Hepatic Glycogen,
·cytosolic Protein , Microsomal
Protein, P-450, Microsomal
Phospholipid, Mic;rosomal Fatty
Acid, Microsomal Cholesterol.
and Total Microsomal Lipid
Following48hr Glucose
Administration
Hepatic glycogen content was measured by solubilizing a
small piece of liver tissue (O.l g) in 30% KOH at 5o 0 c for
one hour and then precipitating the glycogen in 95% ETOH at

ioo 0 c.

The glycogen precipitate was resuspended in water

and then reacted under alkaline conditions with anthrone
(50).

Hepatic cytosolic and microsomal protein was deter-

mined by the Lowry method (51).
Microsomal P-450 content was measured by the absorbance
difference in dithionite reduced microsomal suspension and a
dithionite reduced microsomal suspension mixed with carbon
monoxide (46).

Microsomal lipid was extracted with 1 part

chloroform and 1 part methanol as described by Bligh and
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Dyer (51).

Lipid was stored at

was performed.

-ao 0 c until each analysis

An aliquot of the extracted microsomal lipid

was removed and the phospholipid content was measured by
determining total phosphorus content as previously described
by Bartlett (53).

Microsomal fatty acid content was deter-

mined by reacting an aliquot of extracted lipid with hydroxylamine and ferric chloride under alkaline conditions as
described by Stern and Shapiro (54).

Microsomal cholesterol

content was measured colorometrically by reacting an aliquot
of extracted microsomal lipid with ferric chloride under
acidic conditions (55).

Total microsomal lipid (phospho-

lipid + neutral lipid) was measured by weighing the whole
microsomal lipid extracts after the chloroform solvent was
evaporated.
ouantitation of Specific
Microsomal Faj:ty Acids
by Gas Chromatography
Specific fatty acids were separated and quantitated
by gas chromatography (GC) on a Suppelco Wax 10 column
(Suppelco Inc., Belafont

Pa.).

The fatty acids in a 1 mg

sample of extracted microsomal lipid were transmethylated in
boron trifluoride-methanol (14/100 W/V) at 6o 0 c for 60 min
as previously described (53).

The fatty acid methyl esters

(FAME's) of palmitic, palmitoleic, stearic, and oleic acid
were identified and quantitated using reference FAME's
obtained from Sigma Chemical company (Sigma, St. Louis Mo.)
(56).

The GC operating conditions were set as follows;
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helium gas flow 8 ml/min, detector temp 26o 0 c, injector temp
25o 0 c, column temp program was 200°c for 15 min then elevated to.235°c at 2°c;min and held for 10 min before reequilibration at 200°c.
Separation and Ouantitation of
Microsomal Phosphatidylcholine
and Phosphatidylethanolamirie
The quantitation of phosphatidylcholine and ethanolamine was carried out by TLC.

A 1 mg sample of microsomal

lipid was spotted on silica gel coated thin layer plates
(250 microns).

The plates were developed in two solvent

systems as previously described (57).

The separated phos-

pholipids were stripped from the plates and total phosphorus
was determined (53).
Spectral Binding of Hexobarbital
and Methadone.to Hepatic
Microsomal P-450
The binding of hexobarbital and methadone to microsomal
P-450 was measured spectrally on a Beckman ACTA MVI dual
beam spectrophotometer (Beckman Instruments, Irvine Ca.).

A

0.1 ml aliquot of buffer (1.15% KCl in 0.025 M tris, pH
7.45) was added to disposable 4.0 ml polystyrene reference
and sample cuvettes (pathlength 1.0 cm) which contained

2~9

ml of microsomal suspension at a final protein concentration
of 3.0 mg/ml.

The baseline was obtained by scanning the
/

microsomal suspension from 500 to 360 nm in the split beam
mode.

The ··difference spectrum was obtained by! adding o. 1 ml
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of an appropriate amount of hexobarbital or methadone to
2.9 ml of microsomal suspension to obtain the concentrations
given in the results.

The cuvette containing the drug was

placed in the sample chamber and scanned from 500 to 360 nm.
After the spectral scan was obtained the baseline was subtracted and the difference spectra plotted.

The data was

subjected to a double reciprocal plot to obtain the maximal
spectral binding

(~Amax)

and the spectral dissociation

constant (Ks) as described by Schenkman and Kupfer (58,59).

Chapter 3
RESULTS

Figure 1 describes the effect of 48 hr glucose treatment on the dose response curve of pentobarbital in mice.
Note that glucose treatment appears to shift the curve to
the left which resulted in a reduction of the ED 50 by 5.85
mg/kg (P<O. 05).
Table 1 describes the effect of 48 hr glucose treatment
on the in vitro metabolism of p-Nitroanisole by the liver
9,000 xg supernatant and the microsomal fractions.

With

respect to the 9,000 xg fraction the glucose treated animals
metabolized one half of the substrate (p-Nitroanisole') as
did the controls.

When the microsomal fraction was used the

controls lost 37% of their activity but the glucose treated
only lost approximately 12.5% of their activity (25.17 vs
18.74 Nmoles p-Nitroanisole metabolized/mg protein/30 min).
However the difference in microsomal activity between the
two groups was still highly significant (P<0.01).

When the

control microsomes were re-constituted with control cytosol
they did not regain their original metabolic activity, but
retained the microsomal level of metabolism.

The microsomes

from the treated animals reconstituted with cytosol from
controls showed a slight increase in activity.

The recon-

stitution of control microsomes plus cytosol from the
treated animals and vice versa, did not change the activity.
These data suggest that glucose treatment does not affect
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factors in the cytosol other than the possibility of
inducing enzymes that metabolize glucose and that glucose
treatment appears.to have a major influence on the metabolic
activity of the microsomal fraction of the liver cell.

Table 1
NMoles p-Nitrophenol Formed/Mg
Microsomal Protein/JO min

Group
Control

9,000 xg

±

40.4

3.3

Microsomes
25.2 + 1.3

CM+CC
26.4

± 0.93

TM+TC
Glucose
Treated

21.4 + 0.22

18.7 + 0.7

p < 0.01
N

CM+CC
TM+TC
CM+TC
TM+CC

=
=
=
=

Control
Treated
Control
Treated

=

p < 0.01

20

Microsomes
Microsomes
Microsomes
Microsomes

N

+
+
+
+

=

20

Control
Treated
Treated
Control

20.9 + 0.2

p < 0.01
N

= 20

CM+TC
26.8 + 0.9

TM+CC

21.9 + 0.4

p < 0.01
N

=

20

Cytosol
Cytosol
cytosol
Cytosol

Spectral binding studies of hexobarbital and methadone
to rat microsomal P-450 were carried out in order to examine
further the effect of glucose treatment on the microsomal
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Figure 1. The effect of 48 hr glucose administration on the
dose response curve of pentobarbital in mice. Animals in
each group were injected I.P. with.various doses of
pentobarbital and the number of animals in each group that
exhibited anesthesia (loss of righting reflex) was recorded.
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P-450 system.

The rat was selected as the species due to

the fact that many of the spectral binding studies of various substrates to hepatic P-450 have been carried out in
the rat (15,17,18,19,20,21,22,24,58,59), which provided an
extensive data base for the comparison of control and
treated animals.

Since the binding was to be carried out in

rats rather than mice, it was necessary to examine the
effect of glucose treatment on the barbiturate sleep time,
microsomal protein content and microsomal P-450 content as
previously examined in mice.

The effect of 48 hr glucose

administration on the duration of pentobarbital induced
anesthesia is shown in Figure 2.

Glucose administration

results in a highly significant increase (P<0.005) in
barbiturate induced hypnosis which is consistent with
previous studies showing an increase in barbiturate anesthesia after 48 hr glucose administration in mice.

The

effect of glucose administration on microsomal protein,
cytosolic protein and microsomal P-450 content is shown in
Figure 3.

Glucose administration causes no significant

changes in the microsomal protein or P-450 content but does
induce a significant increase in the cytosolic protein
content in the treatment group.
Effect of Glucose on Spectral
Binding of Hexobarbital and
Methadone to Microsomal P-450
The binding of hexobarbital to microsomal P-450
produced a blue shift (type 1 spectrum) as previously
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published (58).

The binding of methadone to microsomal

P-450 also produced a type 1 spectrum giving an absorption
maximum at 384 nm and a minimum at 421 nm as shown in Figure
4.

The spectral changes produced by the binding of these

compounds were concentration dependent and showed saturabili ty with increasing amounts of drug added to the microsomal suspension.
Figure 5 shows a plot of the (L\A) absorbance changes
at 420 nm versus the concentration of hexobarbital in the
microsomal suspension.

This figure shows a decrease in the

binding of hexobarbital to hepatic microsomal P-450 after
48 hr glucose administration.

Figure 6 is a plot of the .1 A

values at 421 nm versus the concentration of methadone in
the microsomal suspension.

Glucose administration once

again is associated with a reduction in the binding of a
substrate to microsomal P-450.

Figure 7 is a double recip-

rocal plot of .1 A at 420 nm versus the concentration of
hexobarbital.

This figure shows that the administration of

glucose results in a decrease in the apparent spectral dissociation (Ks) and a decrease in the apparent maximal spectral binding (L\Amax) of hexobarbital to hepatic P-450.
These data are consistent with the previously observed
decrease in apparent Km and Vmax for the microsomal metabolism of hexobarbital in mice following 48 hr glucose administration (46).

Figure 8 is a double reciprocal plot illus-

trating the effect of 48 hr glucose administration on the
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binding of methadone to hepatic P-450.

Note that glucose

administration results in an increase in the apparent Ks and
a decrease in the apparent J Amax.

These data are also

consistent with the previously observed increase in apparent
Km and a decrease in the apparent Vmax for the hepatic
microsomal metabolism of methadone in mice following 48 hr
glucose administration (47).
The spectral binding of hexobarbital and methadone to
rat hepatic microsomal P-450 are summarized in Figures 9 and
10.

The two notable features of these figures are (a) the

effect of glucose treatment on the apparent Ks (decreased Ks
for hexobarbital and increased Ks for methadone) for both
hexobarbital and methadone and (b) the decrease in the
apparent JAmax per unit of P-450 for both hexobarbital and
methadone in the glucose treated animals.

The decrease in

binding of hexobarbital to P-450 in the treated group is
approximately 22% as compared to controls.

The decrease in

binding of methadone to P-450 in the treated group is
approximately 12% as compared to the controls.

The data

from these studies suggest that glucose treatment alters the
binding of hexobarbital and methadone to hepatic microsomal
P-450.
Figure 11 illustrates the effect of glucose administration on liver, glycogen content, microsomal phospholipid
content, total microsomal fatty acids and microsomal cholesterol content.

Glucose treatment produces a reduction in
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glycogen content (16% reduction in treated animals as
compared with controls).

Phospholipid content and total

fatty acid content in the microsomes increase significantly
(P<0.02 and P<0.005 respectively) following glucose treatment. The increase in phospholipid content in the treated
animals is approximately 26% as compared to controls and the
increase in fatty acid content in the treated animals is
approximately 22% as compared to controls.

It is interes-

ting to note that a 22% increase in microsomal fatty acid
content is associated with a 22% decrease in the maximal
spectral binding of hexobarbital to P-450 and a 12% reduction in the binding of methadone to P-450.
Glucose administration appears to have an effect on
total microsomal lipid content and on the content of various
fatty acid in the microsomal membrane (Figure 12).

Glucose

administration results in highly significant increases in
palmitic, palmitoleic and oleic acid (P<0.005).

There is

also an increase in stearic acid, but the level of signif icance (P<0.05) is not as great as the other three fatty
acids.

These data may suggest that glucose is being

converted to specific fatty acids and consequently lipid
which can then be deposited in the microsomal membrane.
Quantitation of the two predominant lipids in the
microsomal membrane, phosphatidylcholine (PC) and
phosphatidylethanolamine (PE), following glucose administration is shown in Figure 13.

These data show that glucose
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administration results in a significant increase in both PC
and PE (P<0.02 and P<0.05 respectively).

The increase in PC

content was 33% and the increase in PE content was approximately 22% over the control values.

Chapter 4
DISCUSSION
Previous studies have shown that 48 hr glucose
administration result in a significant increase in the
duration of pentobarbital induced anesthesia and opiate
induced analgesia (45,46,47).

The data reported in these

studies confirmed the glucose effect showing that glucose
administration decreases the amount of pentobarbital necessary to achieve anesthesia (Figure 1).

A possible theory

explaining the effect of glucose administration on the duration of action of barbiturates and opiate analgesics is that
glucose administration may somehow reduce the hepatic microsomal metabolism of these two groups of drugs.

The reduced

metabolism might then lead to higher blood levels of the
drugs and hence prolonged effect.

One study showed that

mice treated for 48 hrs with glucose had higher blood levels
of pentobarbital (46) and that the hepatic in vitro microsomal metabolism of compounds such as p-Nitroanisole, pentobarbital, hexobarbital and methadone were significantly
reduced (45,46,47).

The data presented in Table 1 confirm

that glucose administration does indeed impair the in vitro
hepatic microsomal metabolism of p-Nitroanisole in mice.
The data also appear to indicate that a metabolite of
glucose or glucose itself is not directly responsible for
the reduction in metabolism as exemplified by the reconstitution of the cytosolic and microsomal fractions.
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What
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appears to be clear from these data (Table 1) is that the
microsomal system itself is altered in some way after
glucose administration which results in reduced enzymatic
activity.

This information is consistent with previous

observations showing that glucose administration appears to
exert its effect on the hepatic microsomal system resulting
in a significant reduction in P-450 enzyme activity (45,46).
Other animal species such as the rat have been shown to
be affected by the administration of glucose or sucrose.

In

one previously published study the administration of glucose
or sucrose in the diet resulted in prolonged sleep time
after the administration of pentobarbital (35).

The data

presented in Figure 2 are consistent with this previous
observation, showing that 48 hr glucose administration to
rats results in highly significant increases in pentobarbital induced anesthesia.

These data are also consistent

with the previously observed prolonged pentobarbital anesthesia in mice after 48 hr glucose administration (45,46).
The i.p. administration of glucose or sucrose to rats for 7
days will apparently result in a decreased hepatic microsomal P-450 content with a concomitant reduction of the in
vitro microsomal P-450 mediated metapolism of ethylmorphine.
The in vivo assessment of hepatic drug metabolic activity
using the antipyrine test confirmed the parallel decrease in
microsomal activity in vitro (44).

The data reported in our

studies (Figure 3) did not show any significant quantitative
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change in microsomal protein or P-450 content following 48
hr glucose administration.
by Hartshorn, et al.

The previously published studies

(44) reportedly saw no changes in rat

hepatic microsomal protein or P-450 content within 2 days of
initial treatment with glucose or sucrose which is consistent with the data reported in our laboratory (Figure 3).
However significant changes in P-450 content did arise
within 5 days after initial treatment (44).

Peters and

Strother showed that the 48 hr administration of glucose to
mice apparently does not result in a significant quantitative change in hepatic microsomal protein or P-450.content
(46) which is consistent with the data obtained in the rat
as noted in Figure 3.

These results may suggest that the

effect of 48 hr glucose administration on pentobarbital
anesthesia in mice (45,46) and rats is related to reduced
hepatic metabolic activity.

However the data reported here

(Figure 3) and in other published studies (46) do not support the theory that the effect of glucose administrat.ion on
drug action is related to quantitative changes in hepatic
microsomal P-450 content.
Although hepatic microsomal protein content and P-450
content did not significantly change following glucose
treatment, the cytosolic protein content did significantly
increase in the glucose treated animals (Figure 3).

The

increased cytosolic protein content might suggest that the
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increased glucose intake may be inducing enzymes that metabolize glucose or synthesize lipids.
In the absence of significant quantitative changes in
hepatic microsomal P-450 content following 48 hr glucose
treatment, binding studies were carried out to examine the
effect of glucose treatment on the interaction between P-450
and the substrates hexobarbital and methadone.

The binding

of hexobarbital to microsomal P-450 produced a type 1 spectrum with an absorption maximum at 385 nm and minimum at 420
nm which is consistent with previous reports by Schenkman on
the spectral binding of hexobarbital to rat hepatic microsomal P-450 (58).

The binding interaction of methadone to

rat hepatic P-450 also produced a type l spectral shift and
is shown in Figure 4 since its spectrum has not been

pre~

viously published.

The absorption maximum was 384 nm and

minimum at 421 nm.

The.type l spectral shifts produced by

the binding of hexobarbital and methadone indicate a shift
in the spin state of the heme moiety of cytochrome P-450 to
the high spin state (58,60).

Substrates that induce type 1

spectral shifts in microsomal P-450 have been shown to
exhibit a preferential binding to the high spin form of
P-450 (20,61).

The administration of glucose to rats for 48 hrs
results in a significant reduction in the spectral binding
of hexobarbital and methadone to P-450 (Figures 4,5).

The

reduced interaction between microsomal P-450 and these two
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substrates (as indicated by the reduction in spectral
binding) may off er a possible explanation for the previously
observed reduction of the in vitro hepatic microsomal metabolism of hexobarbital in glucose treated mice (46,47).
Plotting the spectral binding data (Figures 7,8) by the
double reciprocal method showed a change in both the spectral dissociation constant (Ks) and the maximal spectral
binding ( .d Amax) for hexobarbi tal and methadone.

Changes in

the spectral binding parameters have been suggested in some
cases to be indicators of qualitative or conformational
changes in P-450 (7,20,58,60,61).

The data presented here

(Figures 7,8) suggest that glucose administration may be
effecting a qualitative change in the microsomal P-450 which
would then be responsible for the decrease in the Li.Amax and
the changes in the Ks.

The increase in Ks for methadone

indicates that the affinity of the microsomal P-450 has
decreased following glucose administration.

The data in

Figure 3 show that P-450 content is not significantly
changed by glucose administration, which provides evidence
that the observed changes in the binding of hexobarbital and
methadone (Figures 7,8) may be due to qualitative or conformational changes in the P-450 enzymes.
The decrease in Ks and

Amax-for the spectral binding

of hexobarbital to P-450 is consistent with the data
reported by Peters and Strother (46) showing a decrease in
'

Km and Vmax for the microsomal metabolism of hexobarbit~l
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following glucose administration in mice.
Ks and decrease in

~Amax

The increase in

(Figure 8) for the spectral

binding of methadone to P-450 is consistent with the data
published by Strother and Chau (47) showing an increase in
Km

and decreased Vmax for the microsomal metabolism of

methadone following glucose administration in mice.

In

these published results (46,47) it was also noted that there
was no significant change in microsomal P-450 content which
suggested that the altered kinetics for the metabolism of
hexobarbital and methadone was possibly due to some physical
change in the microsomal P-450 system as opposed to a
quantitative change in P-450 enzyme content.
The summary of the spectral binding of hexobarbital and
methadone (Figures 9,10) showed that glucose administration
to rats for 48 hrs significantly changes Ks and
hexobarbital and methadone.

~Amax

for

The most notable feature in

these figures is that glucose administration results in a
decrease in

Amax per unit of P-450 for both hexobarbital

(Figure 9) and methadone (Figure 10).

The binding data for

hexobarbital and methadone (Figures 7,8,9,10,) combined with
the quantitative data on P-450 (Figure 3) show that glucose
administration alters the ability of the P-450 system to
bind substrates as compared to the controls.
The precise mechanism by which glucose administration
alters the binding of hexobarbital and methadone to hepatic
microsomal P-450 is not very clear.

Two mechanisms have
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been suggested.

The first possibility is that glucose may

be producing its effect on P-450 in some indirect manner
possibly by altering the physical state of the microsomal
P-450 system possibly through changes in lipid quantity and
type.

In order to consider an "indirect mechanism" for the

glucose effect the fate of glucose in the liver needs to be
considered.

Previous studies by Touvinen and Bender (62)

showed that the feeding of glucose or sucrose results in an
increased lipid content in the rat liver.

MacDonald and

Roberts (63) showed that high glucose and fructose diets
will result in the increased in vivo incorporation of 14 cglucose into liver lipids.

Hartshorn et al. (44) have also

shown that the administration of glucose in the diet will
\

.

result in the increased capacity of the liver to convert
glucose to fatty acids and lipid, while Fitch and Chaikoff
(64) showed that carbohydrate administration produced significant changes in enzymes responsible for the production
of lipids.
The data reported in these studies examine some of the
possible end products of glucose metabolism and the relationship between the end products of glucose metabolism and
the microsomal P-450 system.

The administration of glucose

for 48 hrs resulted in a significant reduction in the
hepatic glycogen content (16% reduction in glucose treated
animals, Figure 11).

Fouts et al. (65) have shown that

reduced liver glycogen content after the administration of
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epinephrine would result in a significant increase in
hexobarbital induced sleep and a reduction in microsomal
metabolic activity.

However in the study reported by Fouts

et al. (65) the hepatic glycogen content was reduced to 42%
of the control value before any significant change in sleep
time or microsomal metabolic activity occurred.

Dixon et

al. (66) showed that hepatic microsomal enzyme activity and
glycogen content are not always correlated.

Although the

reduction in glycogen content reported here was significant,
it is difficult in light of other studies (65,66) to make
any inference as to the contribution of the observed change
in glycogen content and the increase in pentobarbital sleep
time.
Glucose administration for 48 hrs did not result in a
significant change in hepatic microsomal cholesterol content
(Figure 11) which is consistent with other published studies
showing that sucrose enriched diets (62) and glucose
enriched diets (67) do not alter hepatic cholesterol
content.
Hepatic microsomal phospholipid content and fatty acid
content apparently increase following 48 hr glucose treatment (Figure 11).

These data may possibly indicate that

glucose is being converted to lipids which are then deposited in the microsomal membrane.

The increased microsomal

lipid content is consistent with the increase in cytosolic
protein content (Figure 3) which might suggest that glucose
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administration is inducing enzymes that metabolize glucose
and/or synthesize lipid.

Other studies have shown increases

in total hepatic lipid content (62,67) following glucose or
sucrose administration.

The data gathered here (Figure 11)

show that lipid content is specifically increased within the
endoplasmic reticulum.

Studies in the past have shown that

lipid is a necessary component in maintaining the appropriate physical state and hence activity of P-450 (9,12).
Therefore it is possible that altered lipid content in the
microsomal membrane may cause a physical change in P-450 as
indicated by the altered binding of hexobarbital and methadone to microsomal P-450 following glucose administration
(Figures 7,8,9,10).
Wade and Norred (68) showed that the feeding of 3%-10%
corn oil to rats resulted in an increase in microsomal lipid
and a corresponding increase of the in vitro microsomal
metabolism of ethylmorphine and hexobarbital.

Hexobarbital

induced anesthesia was also found to be reduced in the
animals fed the high fat diet.

Gower and Willis (69)

conducted a study in which rats were fed a fat diet rich in
C20:5 and C22:6 fatty acids.

These fatty acids were found

to be incorporated into the intestinal microsomal lipids.
The change in lipid content and specific fatty acid type
resulted in an increased rate of P-450 mediated metabolism
of benzo[a]pyrene.

These two studies indicate that changes

in microsomal lipid content (68) and lipid type (69) will
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produce a change (increase) in P-450 activity.

It is

interesting to note that the administration of carbohydrate
appears to produce the opposite effect on P-450 mediated
metabolism of drugs, resulting in a decrease of P-450
activity and a corresponding increase in the duration of
action of various drugs (35,45,46,47).
The administration of glucose was shown in these
studies to have a significant effect on the specific fatty
acid content within the microsomal membrane as shown in
Figure 12 and suggest that the hydrophobic environment of
microsomal P-450 may be altered.

The lipid bilayer of the

microsomal membrane has been shown to influence the conformation of microsomal cytochrome P-450 possibly through the
iron spin state within the porphoryin ring (22,23,32).

The

binding of substrates to microsomal P-450 produces spectral
changes which correspond to spin shifts in the iron moiety
of the cytochrome P-450 enzymes.

A shift to a high spin
1:)

state is ref erred to as a type 1 spectral shift (

>.. min 420

nm, >..max 385 nm) and a shift to a low spin state is called
a type 2 spectral shift (
58,60).

>.. min 385 nm, >..max 419 nm)

(22,

The magnitude of spectral change when a substrate

interacts with P-450 is thus a measure of substrate binding
(58,60).

Since the addition of a substrate to microsomal

P-450 can shift the spin equilibria of the ferric heme group
there has been the suggestion that the magnitude of the
observed binding of a smbstrate may depend on the relative

- - - - - ---

----------------------~
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amounts of P-450 in the high or low spin state before a substrate is added {20,22,23).

Thus any perturbation of the

P-450 spin state equilibria could result in an alteration of
the binding of a particular substrate.

One example of the

effect of spin equilibria on the binding of a substrate to
microsomal P-450 is the effect of adrenodoxin on the binding
of cholesterol to cytochrome P-450.

The addition of

adrenodoxin to a microsomal suspension will shift the spin
equilibrium of P-450 to the high spin state which results in
an enhanced binding of cholesterol to P-450 {20).

The addi-

tion of pregnenolone to a microsomal suspension will shift
the spin equilibrium of P-450 to a low spin state which then
reduces the binding of adrenodoxin (20).
Gibson et al.

(23) have attempted to examine the

relationship between P-450 spin state equilibria and the
microsomal lipid.

If microsomal P-450 is reconstituted with

phospholipid and free fatty acids there appears to be a
shift in the spin equilibrium of P-450 from a low to high
spin state.

The shift in spin state resulted in the

enhanced binding of type 1 substrates to P-450.

Furthermore

the report showed that the addition of oleic acid would
shift the spin equilibrium of P-450 to the high spin state
and that palmitic and stearic acid would shift the equilibria to the low spin state (23).

These data suggests that

the fatty acids on the phospholipid play a role in regulating the spin equilibria of P-450 which then affects the
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binding of particular substrates.

The data reported in

Figure 12 show that specific fatty acid changes (especially
palmitic and stearic acid) occurred in the microsomal membrane following glucose administration.

The changes in

lipid content and specific fatty acid types (Figures ll,12)
within the microsomal membrane might be influencing the spin
state and hence conformational states of membrane bound
microsomal P-450.

If indeed the lipid changes in the mem-

brane are partly responsible for conformational changes in
microsomal P-450 then it remains possible that conformational changes in P-450 may be responsible for the observed
reduction in the binding of hexobarbital and methadone to
P-450 following glucose administration (Figures 7,8,9,10).
Whole lipid extracts from the microsomal fraction were
quantitated following glucose administration.

The data

showed that glucose administration resulted in a significant
increase in total lipid content (Figure 12) and a significant increase in the content of the phospholipids, phosphatidylcholine (PC) and phosphatidylethanolamine (PE) as shown
in Figure 13~.
lipids may

Quantitative changes in these two predominant

possibl~

influence the conformational states of

microsomal P-450 and thus the binding of particular
substrates to P-450 as shown in Figures 7 and 8.

However

previous studies have shown that while whole lipid is
important in maintaining the appropriate physical state of
P-450/it is the fatty acid moiety of the phospholipid that
.i
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appears to be the predominant factor in the maintenance of
P-450 spin state equilibria (23).

Thus the alteration of PC

and PE may not be all that important in the observed binding
changes observed in these studies (Figures 7,8), but rather
the quantitative changes in the fatty acid moiety of the
lipid may be more important in terms of their influence on
the conformational states of microsomal P-450.
The second hypothesis for the effect of glucose admin-istration on the activity of hepatic microsomal P-450 is
that glucose or some by product of glucose metabolism may
cause a quantitative change in one or more of the P--450
enzymes.

Although this is a reasonable hypothesis the data

gathered in our laboratory (Figure 3) and published data
(46,47) do not suggest that a significant change in the
amount of P-450 is occurring.

No reports have been located

in the literature of a change in the proportions of the
multiple forms' of cytochrome P-450 following 48 hr glucose
administration.

If rats are treated for 5 to 7 days with

fructose or glucose a significant reduction in P-450 content
can be measured along with a significant reduction in the
microsomal metabolism of substrates such as ethylmorphine,
p-Nitroanisole and aniline (44).

However 48 hr glucose

administration will sensitize mice to the effects of pentobarbital and reduce the metabolic activity of hepatic microsomal P-450 as shown here (Figure 1, Table 2) and in other
studies (45,46,47).

Rats are also sensitized to the effects
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of pentobarbital {Figure 2) by 48 hr glucose administration
and changes in the binding of hexobarbital and methadone
(Figures 7,8,9,10) to microsomal P-450 occur after the
glucose exposure.

The changes in microsomal activity in

mice and the binding changes of drug substrates to rat
microsomal P-450

observed after glucose administration all

occur without significant changes in total microsomal P-450
content.

Therefore the data presented here do not support

the theory that 48 hr glucose administration is altering the
hepatic microsomal P-450 in a quantitative manner.
Future studies that may further elucidate the effect of
glucose administration on the hepatic microsomal·P-450
system would involve the direct spectral examination of the
heme spin states of microsomal P-450 in control and glucose
treated animals.

Possible changes in spin states and the

conformational changes that altered spin equilibria produce
may provide an explanation for the altered P-450 activity
and binding of substrates to P-450 following glucose
administration.

Chapter 5
SUMMARY

The administration of glucose for 48 hrs to mice
resulted in a shift of the dose response curve for pentobarbital, an indication that glucose administration significantly sensitized the animals to the affects of the drug.
The administration of glucose also reduced the microsomal
P-450 catalytic activity as measured by the conversion of
p-Nitroanisole to p-Nitrophenol.

These results were consis-

tent with previously published data and suggest that glucose
administration may produce its effect on drug duration of
action through a reduction in the hepatic metabolism of
various compounds as previously suggested.
The administration of glucose to rats for 48 hrs also
resulted in a prolonged effect of pentobarbital induced
hypnosis.

The spectral binding of hexobarbital and metha-

done was found to be significantly reduced following glucose
administration.

The changes in spectral binding were

observed in the absence of any significant change in the
microsomal P-450 content.

The changes in spectral binding

of hexobarbital and methadone to P-450 in glucose treated
animals might suggest that glucose administration may be
causing a qualitative or a conformational change in hepatic
microsomal P-450 enzymes.

The administration of glucose

resulted in a significant increase in cytosolic protein
content which might suggest that glucose is inducing enzymes
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responsible for its metabolism and/or the synthesis of
lipids from glucose.
In an attempt to understand the possible mechanism(s)
by which glucose exerts its effect on the microsomal P-450
system, the effects of glucose administration were examined.
Glucose treatment results in a significant reduction of
hepatic glycogen content.

Glucose treatment did result in

significant increases in total microsomal lipid, phospholipid, and fatty acid content.

Specific microsomal fatty

acid and phospholipid contents were also measured following
glucose administration.

These results showed there was a

significant increase in microsomal palmitic, palmitoleic,
stearic, and oleic acids as well as the phospholipids
phosphatidylcholine and phosphatidylethanolamine.

Changes

in lipid content and specific fatty acid content have been
shown to be associated with changes in microsomal P-450
activity and the binding of various substrates to P-450.
Changes in fatty acids within the membrane have been
associated with alterations in the P-450 heme spin states
which in turn produce qualitative or conformational changes
in the P-450 enzymes as measured by spectral binding of
substrates.

Conformational changes in P-450 can enhance or

reduce the binding of various substrates to P-450.

Th& data

reported in these studies suggest that glucose administration was associated with quantitative changes in specific
microsomal lipids and that these lipid changes could have
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influenced the activity of microsomal P-450 and the binding
of drug substrates to P-450.
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